Pursuant to Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby submit the Standalone and Consolidated ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Riddhi Siddhi Gluco Biols reported Q3 FY26 standalone revenue from operations of Rs 3,123.92 lakhs, marginally down from Rs 3,189.66 lakhs a year ago, while standalone profit after tax fell sharply to Rs 886.05 lakhs from Rs 2,662.85 lakhs in Q3 FY25. On a 9-month basis, standalone revenue from operations surged to Rs 20,194.52 lakhs from Rs 7,468.59 lakhs, largely driven by the trading business segment, but 9-month PAT declined to Rs 5,112.98 lakhs from Rs 8,413.52 lakhs. On a consolidated basis, Q3 FY26 showed a net loss of Rs 128.62 lakhs versus a loss of Rs 5,401.72 lakhs in Q3 FY25 (which had absorbed a Rs 6,956.48 lakhs impairment in the subsidiary's discontinued paper division). The auditor flagged an Emphasis of Matter regarding a Rs 308 lakh income-tax contingent liability and the ongoing disposal of the paper division assets.
Short-term shareholders may react negatively to the sharp Q3 standalone PAT drop and the persistent quarterly loss at the consolidated level, though the year-on-year improvement is largely due to a non-recurring impairment in the base quarter. The Rs 308 lakh tax contingent liability and unresolved SEBI/SAT matters remain overhangs, while growth in the trading business is offset by weak operating margins.